|
1）Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009; 187: 761-72
|
|
|
|
2）Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011; 10: 253-63
|
|
|
|
|
|
3）Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya J Med Sci. 2015; 77: 537-49
|
|
|
|
|
|
4）Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004; 15: 601-9
|
|
|
|
|
|
5）Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimerʼs disease. N Engl J Med. 2013; 368: 107-16
|
|
|
|
|
|
6）Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimerʼs disease. N Engl J Med. 2013; 368: 117-27
|
|
|
|
|
|
7）Cady J, Koval ED, Benitez BA, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014; 71: 449-53
|
|
|
|
|
|
8）Chiu IM, Morimoto ET, Goodarzi H, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013; 4: 385-401
|
|
|
|
|
|
9）Frakes AE, Ferraiuolo L, Haidet-Phillips AM, et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014; 81: 1009-23
|
|
|
|
|
|
10）Butovsky O, Jedrychowski MP, Cialic R, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015; 77: 75-99
|
|
|
|
|
|
11）Parisi C, Arisi I, DʼAmbrosi N, et al. Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 2013; 4: e959
|
|
|
|
|
|
12）Koval ED, Shaner C, Zhang P, et al. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet. 2013; 22: 4127-35
|
|
|
|
|
|
13）Henkel JS, Beers DR, Wen S, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013; 5: 64-79
|
|
|
|
|
|
14）Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012; 122: 3063-87
|
|
|
|
|
|
15）Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008; 11: 251-3
|
|
|
|
|
|
16）Papadeas ST, Kraig SE, OʼBanion C, et al. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc Natl Acad Sci U S A. 2011; 108: 17803-8
|
|
|
|
|
|
17）Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011; 29: 824-8
|
|
|
|
|
|
18）Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014; 81: 1001-8
|
|
|
|
|
|
19）Kong Q, Chang LC, Takahashi K, et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Invest. 2014; 124: 1255-67
|
|
|
|
|
|
20）Guo Y, Zhang Y, Wen D, et al. The modest impact of transcription factor Nrf2 on the course of disease in an ALS animal model. Lab Invest. 2013; 93: 825-33
|
|
|
|
|
|
21）Sasabe J, Chiba T, Yamada M, et al. D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J. 2007; 26: 4149-59
|
|
|
|
|
|
22）Sasabe J, Miyoshi Y, Suzuki M, et al. D-amino acid oxidase controls motoneuron degeneration through D-serine. Proc Natl Acad Sci U S A. 2012; 109: 627-32
|
|
|
|
|
|
23）Mitchell J, Paul P, Chen HJ, et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A. 2010; 107: 7556-61
|
|
|
|
|
|
24）Endo F, Komine O, Fujimori-Tonou N, et al. Astrocyte-derived TGF-beta1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015; 11: 592-604
|
|
|
|
|
|
25）Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013; 74: 20-38
|
|
|
|
|
|
26）Philips T, Bento-Abreu A, Nonneman A, et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain. 2013; 136: 471-82
|
|
|
|
|
|
27）Kang SH, Li Y, Fukaya M, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013; 16: 571-9
|
|
|
|
|
|
28）Boillee S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006; 312: 1389-92
|
|
|
|
|
|
29）Lee Y, Morrison BM, Li Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012; 487: 443-8
|
|
|
|
|
|
30）Swarup V, Phaneuf D, Dupre N, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med. 2011; 208: 2429-47
|
|
|
|
|
|
31）Tong J, Huang C, Bi F, et al. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 2013; 32: 1917-26
|
|
|
|
|
|
32）Haidet-Phillips AM, Gross SK, Williams T, et al. Altered astrocytic expression of TDP-43 does not influence motor neuron survival. Exp Neurol. 2013; 250: 250-9
|
|
|
|
|
|
33）Serio A, Bilican B, Barmada SJ, et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2013; 110: 4697-702
|
|
|
|
|